FIGURE

FIGURE 4

ID

ZDB-FIG-231228-133

Publication

Valencia-Sama et al., 2023 - SHP2 inhibition with TNO155 increases efficacy and overcomes resistance of ALK inhibitors in neuroblastoma

Other Figures

All Figure Page

Back to All Figure Page

FIGURE 4

TNO155 and lorlatinib treatment delays tumor growth in ALK-mutant mouse xenografts. A, Tumor volumes of Kelly xenografts treated orally with high- or low-dose regimens of TNO155, lorlatinib, combination treatment (Combo), or vehicle control for 4 weeks. Tumor growth (B) and Kaplan–Meier survival curves (C) of Kelly xenografts treated with high-dose vehicle (n = 5), TNO155 (n = 4), lorlatinib (n = 5), or combination (Combo, n = 4) treatments. Tumor growth (D) and Kaplan–Meier survival curves (E) of Kelly xenografts treated with low-dose vehicle (n = 3), TNO155 (n = 3), lorlatinib (n = 3), or combination (Combo, n = 4) treatments F, Protein expression analyses of tumor lysates treated with vehicle control (n = 3), TNO155 (7.5 mg/kg twice per day, n = 3), lorlatinib (1 mg/kg twice per day, n = 3), or combination (Combo, n = 3) for 20 days. *, P < 0.05; **, P < 0.01; n.s., not significant.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Cancer Res Commun